Compare
Polomar Health Services, Inc. vs BioXcel Therapeutics, Inc. vs Lexaria Bioscience Corp. vs PMGC Holdings Inc.
| Latest fiscal year | Polomar Health Services, Inc. PMHS | BioXcel Therapeutics, Inc. BTAIQ | Lexaria Bioscience Corp. LEXX | PMGC Holdings Inc. ELAB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-08-31 | 2025-12-31 |
| Revenue | $648.2K | $642.0K | $705.9K | $590.1K |
| Revenue growth (YoY) | n/m | -71.7% | +52.0% | n/a |
| Gross margin | 71.0% | 74.5% (computed) | 99.6% | 31.4% |
| Operating margin | n/m | n/m | n/m | n/a |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$10.70M | -$69.90M | -$11.90M | -$7.75M |
| EPS (Diluted) | -$0.39 | -$5.73 | -$0.66 | n/a |
| Operating cash flow | -$396.0K | -$57.62M | -$10.45M | -$5.93M |
| Free cash flow | n/a | -$57.62M | -$10.48M | -$6.38M |
| Cash & equivalents | $132.2K | $28.41M | n/a | n/a |
| Total assets | $390.0K | $44.92M | $4.18M | $12.87M |
| Total liabilities | $1.61M | $140.38M | $1.57M | $5.03M |
| Shareholders' equity | -$1.22M | -$95.46M | $2.99M | $7.84M |
| Return on year-end equity | n/a | n/a | -398.1% | -98.9% |
| Shares outstanding | 28.02M | 22.33M | 19.56M | 80.7K |
Revenue, most recent five fiscal years
| Fiscal year | Polomar Health Services, Inc. | BioXcel Therapeutics, Inc. | Lexaria Bioscience Corp. | PMGC Holdings Inc. |
|---|---|---|---|---|
| Latest | $648.2K Ended 2025-12-31 | $642.0K Ended 2025-12-31 | $705.9K Ended 2025-08-31 | $590.1K Ended 2025-12-31 |
| 1 year earlier | $58.8K Ended 2024-12-31 | $2.27M Ended 2024-12-31 | $464.3K Ended 2024-08-31 | n/a |
| 2 years earlier | $41.8K Ended 2023-12-31 | $1.38M Ended 2023-12-31 | $226.2K Ended 2023-08-31 | $1.71M Ended 2023-12-31 |
| 3 years earlier | $34.5K Ended 2022-12-31 | $375.0K Ended 2022-12-31 | $255.4K Ended 2022-08-31 | $766.3K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $722.7K Ended 2021-08-31 | n/a |